- Conditions
- Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Carcinoma, Breast
- Interventions
- Neoadjuvant endocrine therapy
- Drug
- Lead sponsor
- George Washington University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,211
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Breast Cancer
- Interventions
- Cyclophosphamide, Docetaxel, Doxorubicin, Tamoxifen
- Drug
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- Female only
- Enrollment
- 2,411 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2010
- U.S. locations
- 134
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Greenbrae, California + 115 more
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Hormone Receptor Positive Breast Adenocarcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
- Interventions
- Magnetic Resonance Imaging, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Triple Negative Breast Cancer
- Interventions
- ProAgio Dose Levels (DL) 1,2,3,4, ProAgio Dose Expansion
- Drug
- Lead sponsor
- ProDa BioTech, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Positron-Emission Tomography, Immunomodulation, Metastatic Solid Malignancies, Hodgkin Lymphoma
- Interventions
- ⁸⁹Zr-Df-IAB22M2C Infusion
- Drug
- Lead sponsor
- ImaginAb, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • New York, New York • Philadelphia, Pennsylvania
- Conditions
- Advanced/Metastatic Solid Tumors
- Interventions
- NMS-03305293
- Drug
- Lead sponsor
- Nerviano Medical Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Solid Tumors, Ovarian Cancer, Endometrial Cancer
- Interventions
- ARQ 092 + carboplatin + paclitaxel (Closed), ARQ 092 + paclitaxel (Closed), ARQ 092 + anastrozole
- Drug
- Lead sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 5
- States / cities
- Grand Rapids, Michigan • New York, New York • Oklahoma City, Oklahoma + 2 more
- Conditions
- Breast Carcinoma, Prostate Carcinoma
- Interventions
- Aromatherapy with Essential Oils
- Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Breast Cancer, Cancer Survivor, Hot Flashes
- Interventions
- hot flashes attenuation, hypnotherapy
- Procedure
- Lead sponsor
- Scott and White Hospital & Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Temple, Texas
- Conditions
- Breast Cancer, Ductal Carcinoma in Situ
- Interventions
- Not listed
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Depression, Breast Cancer, Stress, Breast Cancer Non-invasive Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Cancer Metastatic Breast Cancer
- Interventions
- Videoconferencing support group
- Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Medical Oncology
- Interventions
- BAY1217389, Paclitaxel
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 6
- States / cities
- Santa Monica, California • Denver, Colorado • New Haven, Connecticut + 3 more
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Magrolimab, Olaparib
- Procedure · Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 5
- States / cities
- Costa Mesa, California • Orange, California • The Bronx, New York + 1 more
- Conditions
- TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease
- Interventions
- Not listed
- Lead sponsor
- Personalis Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 422 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 14
- States / cities
- Tucson, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 11 more
- Conditions
- Anxiety Disorder, Depression, Ductal Breast Carcinoma in Situ, Fatigue, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Interventions
- yoga therapy, internet-based intervention, questionnaire administration
- Procedure · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Metastatic Breast Cancer
- Interventions
- MK-0752, Docetaxel, Pegfilgrastim
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan • Houston, Texas
- Conditions
- Advanced Solid Tumors, Excluding Breast Cancer
- Interventions
- caffeine, diclofenac, omeprazole, midazolam, TKI258
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 5
- States / cities
- Kansas City, Kansas • Detroit, Michigan • Minneapolis, Minnesota + 2 more
- Conditions
- Breast Cancer
- Interventions
- INCB007839 300mg BID, Trastuzumab, Vinorelbine
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 14
- States / cities
- Fayetteville, Arkansas • Duarte, California • Denver, Colorado + 11 more
- Conditions
- Recurrent Breast Cancer, Stage IV Breast Cancer
- Interventions
- sorafenib tosylate, anastrozole
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Stage I Breast Cancer
- Interventions
- Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
- Other · Drug
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 50 Years to 70 Years
- Enrollment
- 1,670 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2041
- U.S. locations
- 812
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Kingman, Arizona + 553 more
- Conditions
- Breast Cancer
- Interventions
- Doxil, heat treatment
- Drug · Procedure
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 18 Years to 90 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Breast Cancer, Cardiac Toxicity
- Interventions
- management of therapy complications
- Procedure
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 105
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
- Conditions
- Breast Cancer
- Interventions
- Gedatolisib, Faslodex, Palbociclib, Zoladex
- Drug
- Lead sponsor
- Hoffman Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 2
- States / cities
- Los Angeles, California • The Bronx, New York
- Conditions
- Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Residual Disease
- Interventions
- α-lactalbumin vaccine, Zymosan
- Biological
- Lead sponsor
- George T. Budd
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio